GRAIL, Inc.
NMS: GRALLive Quote
📈 ZcoreAI Score
Our AI model analyzes GRAIL, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GRAL Z-Score →About GRAIL, Inc.
Healthcare
Diagnostics & Research
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
📊 Fundamental Analysis
GRAIL, Inc. demonstrates a profit margin of -277.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 14.0% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -16.1%, which indicates that capital utilization is currently under pressure.
At a current price of $45.63, GRAL currently sits at the 23rd percentile of its 52-week range (Range: $23.80 - $118.84).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.87B
Trailing P/E
--
Forward P/E
-5.42
Beta (5Y)
--
52W High
$118.84
52W Low
$23.80
Avg Volume
1.34M
Day High
Day Low